Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Autoantibodies indicating diagnostic or prognostic value in NSCLC patients were identified by protein microarrays.

Sub-category:
Metastatic Non-Small Cell Lung Cancer

Category:
Lung Cancer—Non-Small Cell Metastatic

Meeting:
2019 ASCO Annual Meeting

Abstract No:
e20638

Citation:
J Clin Oncol 37, 2019 (suppl; abstr e20638)

Author(s): Rongrong Luo, Caixia Liang, Jiarui Yao, Di Wu, Zhishang Zhang, Yuankai Shi, Xiaohong Han; Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China

Abstract Disclosures

Abstract:

Background: Autoantibodies(AAbs) have been recently recognized as auxiliary diagnostic biomarkers in lung cancer. Applying high-throughput protein microarrays to address AAbs profile of non-small cell lung cancer(NSCLC) is rarely studied. Herein, we aimed to discover AAbs possessing diagnostic or prognostic value in NSCLC patients. Methods: We collected pretreatment plasma samples and survival data of 258 NSCLC patients and 343 controls. The advanced NSCLC patients were divided into subgroups according to different epidermal growth factor receptor(EGFR) gene status, therapies and therapeutic response. We utilized human proteomic(HuprotTM) microarrays to screen differential AAbs and customized microarrays to validate. Statistical methods were Chi-square test and ROC analysis. Results: We found 8 AAbs(p < 0.05 or AUC > 0.6) with underlying diagnostic or prognostic value of NSCLC patients after screening and validation. The positive rate of 4 AAbs including anti-TP53, XAGE1A1,2 and KCNAB1 in NSCLC group were higher than that in controls. Among them, anti-KCNAB1 increased in early-stage group compared with controls, indicating early diagnostic value. The other three AAbs level raised as disease progressed to advanced-stage. For advanced NSCLC patients, the differential AAbs of EGFR+ patients receiving either first generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy or chemotherapy were identified with higher positive rate in poor response subgroups compared with good response subgroups(Table1). However, for EGFR- patients with chemotherapy, the differential AAbs in different response subgroups were not found. Conclusions: We found AAbs with underlying diagnostic or prognostic value for advanced NSCLC patients receiving EGFR-TKI or chemotherapy, which should be further investigated to confirm their clinical value.

The positive rate(%) of AAbs in different groups of NSCLC patients.

Groups(NO)anti-TP53anti-XAGE1A1anti-XAGE1A2anti-KCNAB1anti-BLOC1S4anti-TPK1anti-NUDT11anti-DDX53
Control(343)2.964.576.995.11----
NSCLC(258)8.8425.7024.1013.25----
IA-IIB(84)4.556.064.5513.64----
IIIB-IV(174)10.3832.7931.1513.11----
EGFR+ TKI (71)*
good response(46)*----2.780.00--
poor response(25)*----6.676.67--
EGFR+ chemotherapy(60)*
good response(18)*-----0.000.000.00
poor response(42)*-----9.3812.56.25
EGFR- chemotherapy(43)*--------

*EGFR+/-:EGFR active mutation/wild-type;(advanced-stage NSCLC) good response: PFS≥10months, poor response: PFS < 10months.

 
Other Abstracts in this Sub-Category:

 

1. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 102 First Author: Ferdinandos Skoulidis
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

2. Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 110 First Author: Sean Khozin
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

3. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9000 First Author: Kazuhiko Nakagawa
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

More...